
## Seamas C Donnelly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1026697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detailed Identification of Plasma Proteins Adsorbed on Copolymer Nanoparticles. Angewandte Chemie - International Edition, 2007, 46, 5754-5756.	7.2	721
2	Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet, The, 1993, 341, 643-647.	6.3	696
3	Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine, 1999, 5, 662-668.	15.2	675
4	Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine, 1997, 3, 320-323.	15.2	413
5	Diastolic Heart Failure. Circulation, 2007, 115, 888-895.	1.6	407
6	A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes and Immunity, 2002, 3, 170-176.	2.2	341
7	Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1617-1628.	2.5	317
8	IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 367-372.	3.3	307
9	Role of selectiris In development of adult respiratory distress syndrome. Lancet, The, 1994, 344, 215-219.	6.3	259
10	Elevated Levels of Interleukin-8 in Donor Lungs Is Associated with Early Graft Failure after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 259-265.	2.5	242
11	The Association between Mortality Rates and Decreased Concentrations of Interleukin-10 and Interleukin-1 Receptor Antagonist in the Lung Fluids of Patients with the Adult Respiratory Distress Syndrome. Annals of Internal Medicine, 1996, 125, 191.	2.0	219
12	Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma Journal of Clinical Investigation, 1998, 101, 2869-2874.	3.9	200
13	Role for macrophage migration inhibitory factor in asthma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14410-14415.	3.3	199
14	Macrophage Migration Inhibitory Factor: A Probable Link between Inflammation and Cancer. Immunity, 2007, 26, 281-285.	6.6	187
15	Inflammation and cancer: macrophage migration inhibitory factor (MIF)the potential missing link. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 831-836.	0.2	181
16	Plasma elastase levels and the development of the adult respiratory distress syndrome American Journal of Respiratory and Critical Care Medicine, 1995, 151, 1428-1433.	2.5	157
17	The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1442-1450.	2.5	149
18	Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax, 2018, 73, 134-144.	2.7	144

#	Article	IF	CITATIONS
19	What is Connected Health and why will it change your practice?. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 703-707.	0.2	124
20	Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Trends in Molecular Medicine, 1997, 3, 502-507.	2.6	120
21	Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochemical and Biophysical Research Communications, 2006, 347, 895-903.	1.0	119
22	Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. Medicinal Research Reviews, 2016, 36, 440-460.	5.0	108
23	Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 2009, 11, 191-197.	2.9	107
24	Enhanced pulmonary inflammation in organ donors following fatal non-traumatic brain injury. Lancet, The, 1999, 353, 1412-1413.	6.3	104
25	The Regulation of Interleukin-8 by Hypoxia in Human Macrophages—A Potential Role in the Pathogenesis of the Acute Respiratory Distress Syndrome (ARDS). Molecular Medicine, 2001, 7, 685-697.	1.9	96
26	Effectiveness of Pulmonary Rehabilitation in Restrictive Lung Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2006, 26, 237-243.	0.5	94
27	Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). European Journal of Internal Medicine, 2013, 24, 597-603.	1.0	93
28	Cystic Fibrosis, Disease Severity, and a Macrophage Migration Inhibitory Factor Polymorphism. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1412-1415.	2.5	88
29	Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. Journal of Endocrinology, 2003, 179, 15-23.	1.2	74
30	Association of MMP - 12 polymorphisms with severe and very severe COPD: A case control study of MMPs - 1, 9 and 12in a European population. BMC Medical Genetics, 2010, 11, 7.	2.1	70
31	Cellular mechanisms of acute lung injury: implications for future treatment in the adult respiratory distress syndrome Thorax, 1992, 47, 260-263.	2.7	66
32	Imbalance in the Expression of CXC Chemokines Correlates with Bronchoalveolar Lavage Fluid Angiogenic Activity and Procollagen Levels in Acute Respiratory Distress Syndrome. Journal of Immunology, 2002, 169, 6515-6521.	0.4	64
33	Nanotechnology based therapeutics for lung disease. Thorax, 2019, 74, 965-976.	2.7	64
34	Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Critical Care Medicine, 2002, 30, 2335-2337.	0.4	62
35	Modulation of human endothelial thrombomodulin by neutrophils and their release products American Journal of Respiratory and Critical Care Medicine, 1997, 155, 47-52.	2.5	61
36	Cryptic haplotypes ofSERPINA1confer susceptibility to chronic obstructive pulmonary disease. Human Mutation, 2006, 27, 103-109.	1.1	59

#	Article	IF	CITATIONS
37	Macrophage migration inhibitory factor is associated with aneurysmal expansion. Journal of Vascular Surgery, 2003, 37, 628-635.	0.6	57
38	Potential pro-inflammatory effects of soluble E-selectin upon neutrophil function. European Journal of Immunology, 1998, 28, 80-89.	1.6	56
39	A Role for Macrophage Migration Inhibitory Factor in the Neonatal Respiratory Distress Syndrome. Journal of Immunology, 2008, 180, 601-608.	0.4	54
40	Initial Serum Ferritin Levels in Patients with Multiple Trauma and the Subsequent Development of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1506-1509.	2.5	53
41	Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. BioFactors, 2009, 35, 165-168.	2.6	53
42	Neutrophil chemokines in bronchoalveolar lavage fluid and leukocyte-conditioned medium from nonsmokers and smokers. European Respiratory Journal, 1998, 12, 1067-1072.	3.1	51
43	Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer. Molecular Medicine, 2014, 20, 729-735.	1.9	47
44	Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 162-169.	2.5	46
45	Nanotechnology in pulmonary medicine. Current Opinion in Pharmacology, 2021, 56, 85-92.	1.7	46
46	Objective assessment of criteria for selection of donor lungs suitable for transplantation. Thorax, 2004, 59, 434-437.	2.7	41
47	The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Medical Genetics, 2011, 12, 24.	2.1	39
48	Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 594-597.	1.4	38
49	A qualitative study of chronic obstructive pulmonary disease patient perceptions of the barriers and facilitators to adopting digital health technology. Digital Health, 2019, 5, 205520761987172.	0.9	38
50	Modulation of pulmonary fibrosis by IL-13Rα2. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L710-L718.	1.3	35
51	The SERPINE2 Gene and Chronic Obstructive Pulmonary Disease. American Journal of Human Genetics, 2006, 79, 184-186.	2.6	34
52	Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. European Respiratory Journal, 2008, 32, 931-937.	3.1	34
53	Small Interfering RNAs Induce Macrophage Migration Inhibitory Factor Production and Proliferation in Breast Cancer Cells via a Double-Stranded RNA-Dependent Protein Kinase-Dependent Mechanism. Journal of Immunology, 2008, 180, 7125-7133.	0.4	32
54	Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease. Respiratory Research, 2021, 22, 133.	1.4	32

#	Article	IF	CITATIONS
55	Reactive Airways Dysfunction Syndrome (RADS) due to chlorine gas exposure. Irish Journal of Medical Science, 1990, 159, 275-277.	0.8	31
56	Smart Nanotherapeutics and Lung Cancer. Pharmaceutics, 2021, 13, 1972.	2.0	28
57	Identification of Novel Genes in Human Airway Epithelial Cells associated with Chronic Obstructive Pulmonary Disease (COPD) using Machine-Based Learning Algorithms. Scientific Reports, 2018, 8, 15775.	1.6	27
58	Role of extracellular vesicles in chronic lung disease. Thorax, 2021, 76, 1047-1056.	2.7	27
59	Pulmonary endothelial permeability and circulating neutrophil-endothelial markers in patients undergoing esophagogastrectomy. Critical Care Medicine, 2000, 28, 3161-3165.	0.4	26
60	CXCL9 Regulates TGF-β1–Induced Epithelial to Mesenchymal Transition in Human Alveolar Epithelial Cells. Journal of Immunology, 2015, 195, 2788-2796.	0.4	26
61	Exploring the barriers and facilitators for the use of digital health technologies for the management of COPD: a qualitative study of clinician perceptions. QJM - Monthly Journal of the Association of Physicians, 2019, 113, 163-172.	0.2	26
62	Inflammatory predictors for the development of the adult respiratory distress syndrome Thorax, 1995, 50, 1023-1026.	2.7	25
63	Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respiratory Medicine: X, 2019, 1, 100004.	1.4	25
64	Exploring the potential benefits of digital health technology for the management of COPD: a qualitative study of patient perceptions. ERJ Open Research, 2019, 5, 00239-2018.	1.1	24
65	Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets, 2015, 19, 507-514.	1.5	23
66	Idiopathic Pulmonary Fibrosis With Emphysema: Evidence of Synergy Among Emphysema and Idiopathic Pulmonary Fibrosis in Smokers. Respiratory Care, 2015, 60, 259-268.	0.8	23
67	Observational Study of a Wearable Sensor and Smartphone Application Supporting Unsupervised Exercises to Assess Pain and Stiffness. Digital Biomarkers, 2019, 2, 106-125.	2.2	22
68	Mediators, mechanisms and mortality in major trauma. Resuscitation, 1994, 28, 87-92.	1.3	21
69	Aerosolized drug-loaded nanoparticles targeting migration inhibitory factors inhibit <i>Pseudomonas aeruginosa</i> -induced inflammation and biofilm formation. Nanomedicine, 2020, 15, 2933-2953.	1.7	21
70	The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue. BMC Cancer, 2020, 20, 916.	1.1	20
71	Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. European Respiratory Journal, 1999, 13, 1029-36.	3.1	20
72	Honeycomb cysts in idiopathic pulmonary haemosiderosis: high-resolution CT appearances in two adults. British Journal of Radiology, 2008, 81, e295-e298.	1.0	19

#	Article	IF	CITATIONS
73	Proteomics and the lung: Analysis of bronchoalveolar lavage fluid. Proteomics - Clinical Applications, 2009, 3, 1044-1051.	0.8	18
74	Airway nitric oxide output is reduced in bronchiectasis. Respiratory Medicine, 2007, 101, 1549-1555.	1.3	17
75	Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis. Thorax, 2020, 75, 449-458.	2.7	17
76	Adalimumab for refractory pulmonary sarcoidosis. Irish Journal of Medical Science, 2016, 185, 969-971.	0.8	15
77	Assessing fibrosis in pulmonary sarcoidosis: late-enhanced MRI compared to anatomic HRCT imaging. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 257-264.	0.2	15
78	Toll-like receptor 3 L412F polymorphism promotes a persistent clinical phenotype in pulmonary sarcoidosis. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 217-224.	0.2	15
79	Macrophage Migration Inhibitory Factor and Acute Lung Injury. Chest, 1999, 116, 111S.	0.4	14
80	A pilot study of the nocturnal respiration rates in COPD patients in the home environment using a non-contact biomotion sensor. Physiological Measurement, 2014, 35, 2513-2527.	1.2	14
81	Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD. European Respiratory Journal, 2007, 30, 810-812.	3.1	12
82	Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 550-562.	2.5	12
83	Review Series–Inflammation & Fibrosis * Introduction. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 503-503.	0.2	10
84	Macrophage migration inhibitory factor enhances <i>Pseudomonas aeruginosa</i> biofilm formation, potentially contributing to cystic fibrosis pathogenesis. FASEB Journal, 2017, 31, 5102-5110.	0.2	10
85	Nuclear Transcription of Long Hairpin RNA Triggers Innate Immune Responses. Journal of Interferon and Cytokine Research, 2007, 27, 789-798.	0.5	9
86	Role of proteomics in the investigation of pulmonary fibrosis. Expert Review of Proteomics, 2007, 4, 379-388.	1.3	9
87	CXCR3 Requirement for the Interleukin-13–Mediated Up-Regulation of Interleukin-13Rα2 in Pulmonary Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 217-225.	1.4	9
88	Post COVID Syndrome (PCS) and healthcare workers: who cares for the carers?. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 611-611.	0.2	9
89	Sarcoidosis and MIF gene polymorphism: a case-control study in an Irish population. European Respiratory Journal, 2006, 29, 325-329.	3.1	8
90	Sarcoidosis, alveolar Â-actin and pulmonary fibrosis. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 897-902.	0.2	7

#	Article	IF	CITATIONS
91	The role of Epsteinâ€Barr virusâ€expressed genes in breast cancer development. Breast Journal, 2020, 26, 2323-2326.	0.4	6
92	Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 475-476.	0.2	5
93	Early Interleukin-22 and Neutrophil Proteins Are Correlated to Future Lung Damage in Children With Cystic Fibrosis. Frontiers in Pediatrics, 2021, 9, 640184.	0.9	4
94	A <scp>crossâ€kingdom</scp> view on the immunomodulatory role of <scp>MIF</scp> / <scp>Dâ€DT</scp> proteins in mammalian and plant <i>Pseudomonas</i> infections. Immunology, 2022, 166, 287-298.	2.0	4
95	A series of patients on anti-TNF therapy referred to a multidisciplinary lung cancer service. Irish Journal of Medical Science, 2013, 182, 135-137.	0.8	3
96	Reply to: Increased prevalence of Sarcoidosis in Ireland. Irish Journal of Medical Science, 2013, 182, 149-149.	0.8	3
97	The lady with the dragon tattoo. Irish Journal of Medical Science, 2017, 186, 157-160.	0.8	3
98	Renal amyloidosis complicating multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2017, 21, 476-477.	0.6	3
99	A qualitative study of clinician perceptions regarding the potential role for digital health interventions for the management of COPD. Health Informatics Journal, 2021, 27, 146045822199488.	1.1	3
100	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 601-601.	0.2	2
101	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 1-1.	0.2	2
102	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 1-1.	0.2	2
103	Traditional Chinese medicine treatment post-stroke and a significant reduction in presentation to healthcare providers. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 397-397.	0.2	2
104	The effects of genetic deletion of Macrophage migration inhibitory factor on the chronically hypoxic pulmonary circulation. Pulmonary Circulation, 2020, 10, 1-13.	0.8	2
105	After acute there is the long-COVID syndrome: what's the plan?. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 1-2.	0.2	2
106	Corticosteroids and "chronic―ARDS. Irish Journal of Medical Science, 1995, 164, 40-41.	0.8	1
107	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 297-298.	0.2	1
108	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 689-689.	0.2	1

#	Article	IF	CITATIONS
109	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 677-677.	0.2	1
110	Chronic disease and assessing quality of life?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 701-701.	0.2	1
111	Building a culture of health in society. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 339-339.	0.2	1
112	Staying safe while waiting for a vaccine: what we need to know. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 705-705.	0.2	1
113	The Early Inflammatory Response in Acute Respiratory Distress Syndrome (ARDS). , 1998, , 153-158.		1
114	Irish thoracic society. Irish Journal of Medical Science, 1994, 163, 196-211.	0.8	0
115	Familial idiopathic pulmonary fibrosis occurring in four members of a family. Respiratory Medicine Extra, 2007, 3, 23-25.	0.1	Ο
116	MIF and Pulmonary Disease. , 2012, , 231-239.		0
117	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 103-104.	0.2	Ο
118	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 881-881.	0.2	0
119	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 785-786.	0.2	0
120	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 1-1.	0.2	0
121	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 977-977.	0.2	Ο
122	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 391-391.	0.2	0
123	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 1065-1065.	0.2	Ο
124	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 249-249.	0.2	0
125	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 599-599.	0.2	Ο
126	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 91-92.	0.2	0

#	Article	IF	CITATIONS
127	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 947-947.	0.2	0
128	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 1-1.	0.2	0
129	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 503-503.	0.2	0
130	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 171-171.	0.2	0
131	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 759-759.	0.2	0
132	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 87-87.	0.2	0
133	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 175-175.	0.2	0
134	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 351-351.	0.2	0
135	Management of vasovagal syncope—where are we today?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 765-765.	0.2	0
136	How do we define when we die?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 221-221.	0.2	0
137	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 77-77.	0.2	0
138	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 147-147.	0.2	0
139	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 365-365.	0.2	0
140	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 503-503.	0.2	0
141	World pulmonary fibrosis conference—ICLAF 2016. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 575-575.	0.2	0
142	Fog in the channel: European science cut-off?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 637-637.	0.2	0
143	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 291-291.	0.2	0
144	Redefining health for the 21st century: investing in well-being—the proper meaning of â€~health-care'. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 197-197.	0.2	0

#	Article	IF	CITATIONS
145	How do doctors define death?. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 119-119.	0.2	0
146	Acromegaly—the importance of early diagnosis. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 409-409.	0.2	0
147	Concussion and sport: players, coaches, doctors—an inconvenient truth. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 777-777.	0.2	0
148	Redefining Health for the 21st. Century—Investing in well-being—the proper meaning of "health-care― QJM - Monthly Journal of the Association of Physicians, 2017, 110, 265-265.	0.2	0
149	Elements 110-01. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 1-1.	0.2	0
150	Why is the United States a sick country?. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 57-58.	0.2	0
151	QJM providing a platform for enhancing our knowledge for rare diseases. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 513-514.	0.2	0
152	Connective tissue diseases-associated interstitial lung disease (CTD-ILD)—where should we go from here?. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 79-79.	0.2	0
153	Digital Health Solutions - the future - but not quite yet. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 153-154.	0.2	0
154	COVID-19: how did China protect their healthcare workers. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 223-223.	0.2	0
155	Acute medical care: time is of the essence. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 289-289.	0.2	0
156	Would Louis Pasteur be accepted for medical school entry today?. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 353-354.	0.2	0
157	BAL Inflammatory Markers of Initiation and Resolution of ALI. Update in Intensive Care and Emergency Medicine, 1998, , 107-118.	0.6	0
158	Announcing the first AoP webinar: â€~Can evidence-based medicine survive in a pandemic?'. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 11-12.	0.2	0
159	Long-term damage by COVID-19 to end organs: don't forget the kidney. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 617-617.	0.2	0
160	COVID-19 and community self-prescribing: a dangerous folly. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 539-539.	0.2	0
161	Long COVID syndrome and the lung: how long will it last?. QJM - Monthly Journal of the Association of Physicians, 2022, , .	0.2	0
162	Association of Physicians of Great Britain and Ireland (www.aopgbi.org)—why not become a member?. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 199-199.	0.2	0

#	Article	IF	CITATIONS
163	Elevated serum ACE levels in patients with post-acute COVID-19 syndrome. QJM - Monthly Journal of the Association of Physicians, 2022, , .	0.2	Ο